PARP1 and ovarian carcinoma: In conclusion, we developed a novel compound, ZC-22, as a CDK4/6 and PARP dual inhibitor, which displays high therapeutic potential for advanced breast and ovarian cancer patients regardless their HR status, either alone or in combination with platinum-based agents.